Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Anika Therapeutics Q3 2026 Results: Net Loss of $311K, Loss Narrows

Anika Therapeutics reported a 10% revenue increase to $30.6 million for the third quarter of 2026, driven by its strategic shift toward OA pain management and regenerative solutions. Despite the revenue growth, the company recorded a net loss of $0.3 million for the quarter, though this was a significant improvement from the $2.3 million net loss in the prior year period.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue30.627.8
Gross profit18.815.6
Profit before tax-0.3-2.2
Net income-0.3-2.3
EPS (diluted, $ a share)$-0.02$-0.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+10.0%
Gross margin61.6%
Operating margin-2.3%
Source

10-Q filed with the SEC, NASDAQ: ANIK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Anika Therapeutics, Inc.: key numbers

Share price
$12.85Close, Nov 17
Market cap
$172M
Shares outstanding
13.4MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Anika Therapeutics, Inc.

All →
7:21 AM ET 8-K
Financial Results

Anika Therapeutics Financial Results

Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, a 10% increase year-over-year driven by 17% growth in its Commercial Channel. The company raised the lower end of its full-year revenue guidance and increased its Adjusted EBITDA outlook following strong performance in its Integrity and international viscosupplement lines.

Term
Q3 2026

“Through the first nine months of 2026, we have executed against the three priorities we established at the start of the year: accelerating revenue growth, strengthening operational execution and advancing our pipeline. We delivered double-digit year to date revenue growth across both channels, secured a long-term agreement that improves the durability and economics of an important commercial relationship, increased manufacturing capacity to support future growth, fully enrolled the Cingal bioequivalence study and expanded Integrity adoption.”

Steve Griffin, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.